Replacing two cycles of intensive chemotherapy with Blincyto raised four-year event-free survival to 83% from 70.3% in children with high-risk B-cell ALL, with far fewer infections.
|Articles|June 11, 2007
- Summer 2007
- Volume 6
- Issue 4
www.re-mission.net
Author(s)Elizabeth Whittington
Gamers take virtual shot at cancer.
Advertisement
Teens and young adults fighting cancer can now really battle the disease with Re-Mission, a video game that pits a robot called Roxxi against cancer cells and bacterial infections, while dealing with side effects at a microscopic level within the bodies of fictional patients. HopeLab, a nonprofit focused on children with chronic illnesses, developed the video game with game developers, animators, psychologists, and scientists. Re-Mission is available free at
Articles in this issue
over 17 years ago
How to Find Helpover 17 years ago
Job Transitions, Insurance Changeover 17 years ago
Medicare Coverage for Colon Cancer Screeningsover 17 years ago
Noting Group Differencesover 17 years ago
The Journey of Cancer Survivorshipover 17 years ago
Beauty Shoppingover 17 years ago
Pregnancy After Cancerover 17 years ago
Fast Facts: Richard Roundtreeover 19 years ago
Portal Authorityover 19 years ago
Precious TumorNewsletter
Stay up to date on cancer updates, research and education
SubscribeAdvertisement
Related to this article
Six years after a B-cell ALL diagnosis at 21, William Yank shares how his view of therapy changed and why he is still working on his mental health.
In a phase 2 study, Ojemda (tovorafenib) led to responses in 43% of adults with melanoma or other solid tumors that carried rare RAF gene changes.
Epkinly plus R-CHOP lowered the risk of disease progression or death by 51% versus R-CHOP alone in patients with newly diagnosed diffuse large B-cell lymphoma.
Advertisement
Advertisement